Physician profile
Carmencita T Lanez
NPI 1770643959
$49,198.97
in general payments reported to CMS, 2019-2025
32 companies · $5,690 in 2025
The $5,690 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,750 · 2020: $7,131 · 2021: $6,118 · 2022: $5,083 · 2023: $12K · 2024: $8,053 · 2025: $5,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,317 · Travel and Lodging: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,550.00 |
| Food and Beverage | $6,317.41 |
| Travel and Lodging | $1,250.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,138.44 | 2021-2025 | |
| Allergan, INC. | $10,341.11 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,336.00 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,194.50 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $1,095.84 | 2019-2022 | |
| Alkermes, INC. | $603.30 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $571.42 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $522.96 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $511.82 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $381.03 | 2022-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $293.15 | 2019-2022 | |
| Tris Pharma INC | $288.48 | 2022-2025 | Dyanavel Xr |
| Rhodes Pharmaceuticals L.P. | $263.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $257.08 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $255.39 | 2019-2025 | Fanapt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $205.83 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $203.87 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $114.97 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $114.49 | 2019-2025 | Wellbutrin |
| Ironshore Pharmaceuticals INC. | $102.14 | 2019-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $74.99 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $64.52 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $56.23 | 2021-2025 | Subvenite, Lamotrigine |
| Janssen Pharmaceuticals, INC | $33.18 | 2020-2022 | |
| Validus Pharmaceuticals LLC | $30.50 | 2020 | |
| Adlon Therapeutics L.P. | $28.62 | 2019-2020 | |
| Shire North American Group INC | $27.33 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.07 | 2019 | |
| Sage Therapeutics, LLC | $17.53 | 2024 | |
| Neuronetics, INC. | $17.31 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.25 | 2019 | |
| Eisai INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmencita Lanez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.